Cerebrospinal Fluid (Csf) Biomarker Panels is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cerebrospinal fluid (CSF) biomarker panels combine multiple analytes to improve diagnostic accuracy and disease monitoring in neurodegenerative diseases. Panels typically include core biomarkers for amyloid, tau, neurodegeneration, and inflammation.[1]
| Biomarker | Abbreviation | Pathological Significance |
|---|---|---|
| Amyloid-β 42 | Aβ42 | Decreased due to plaque formation |
| Amyloid-β 40 | Aβ40 | Reference for Aβ42 ratio |
| Total Tau | t-tau | Neurodegeneration marker |
| Phosphorylated Tau | p-tau181/217/231 | Tau pathology specific |
| Neurofilament Light | NfL | Axonal damage |
| Neurogranin | Ng | Synaptic degeneration |
| Biomarker | Abbreviation | Pathological Significance |
|---|---|---|
| Alpha-synuclein | α-syn | Total, oligomeric, phosphorylated |
| Beta-synuclein | β-syn | Aggregation inhibitor |
| Gamma-synuclein | γ-syn | Neuronal marker |
| Neurofilament Light | NfL | Disease progression |
| Tau | t-tau, p-tau | Neurodegeneration |
| Biomarker | Abbreviation | Pathological Significance |
|---|---|---|
| Neurofilament Light | NfL | Motor neuron damage |
| Phosphorylated Neurofilament | pNfH | Disease severity |
| Chitinase-1 | CHIT1 | Microglial activation |
| YKL-40 | CHI3L1 | Astrogliosis |
| TDP-43 | TDP-43 | Proteinopathy |
This framework allows differentiation of:
Core CSF analytes:
| Condition | Single Biomarker | Panel | Improvement |
|---|---|---|---|
| AD vs. Controls | ~80% | ~90% | +10% |
| AD vs. FTD | ~70% | ~85% | +15% |
| DLB vs. AD | ~65% | ~80% | +15% |
| PD vs. PDD | ~60% | ~75% | +15% |
| Factor | Impact | Mitigation |
|---|---|---|
| Collection | Contamination | Use LP kit |
| Tube type | Adsorption | Siliconized tubes |
| Centrifugation | Cells | 2000xg, 10 min |
| Storage | Degradation | -80°C, avoid freeze-thaw |
| Volume | Dilution | Record CSF volume |
| Platform | Biomarkers | Advantages |
|---|---|---|
| ELISA | Single | Low cost, established |
| Simoa | NfL, p-tau | Ultra-sensitive |
| Lumipulse | Multiple | Automated |
| Mass Spectrometry | Panels | Comprehensive |
The study of Cerebrospinal Fluid (Csf) Biomarker Panels has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| Biomarker | Normal | AD | Note |
|---|---|---|---|
| Aβ42 (pg/mL) | >600 | <500 | Decreased |
| Aβ42/40 ratio | >0.1 | <0.08 | More specific |
| t-tau (pg/mL) | <300 | >450 | Increased |
| p-tau181 (pg/mL) | <50 | >80 | Increased |
| Biomarker | Normal | ALS | Note |
|---|---|---|---|
| NfL (pg/mL) | <800 | >1800 | Strongly elevated |
| pNfH (pg/mL) | <150 | >500 | Motor specific |
Blennow K, et al. "Cerebrospinal fluid biomarkers for Alzheimer's disease." Lancet Neurol. 2022. ↩︎
Jack CR, et al. "NIA-AA Research Framework: AT(N)." Alzheimers Dement. 2018. ↩︎
Kang JH, et al. "PPMI CSF biomarker analysis." Acta Neuropathol. 2019. ↩︎
Zetterberg H, et al. "CSF biomarkers for neurodegeneration." Nat Rev Neurol. 2021. ↩︎